Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$13.18M+77.78%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ryan Rhodes
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 289
- Beta
- -0.03
- Country
- FR
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -1.57
Financials
Revenue
$13.18M+77.8%Net Income
$-14.47MEBITDA
$-8.02MFree Cash Flow
$-4.95M-189.4%EPS (diluted)
$-0.39Shares Outstanding (diluted)
37.53M+72.2%Operating Expenses
$15.35MCash & Debt
$21.54MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $70.75M | $-29.34M | $-0.78 |
| 2024 | $69.35M | $-20.57M | $-0.55 |
| 2023 | $65.32M | $-22.90M | $-0.62 |
| 2022 | $57.92M | $-3.08M | $-0.09 |
| 2021 | $52.08M | $827.4K | $0.03 |
| 2020 | $47.49M | $-1.94M | $-0.07 |
| 2019 | $50.27M | $1.69M | $0.06 |
| 2018 | $46.23M | $-398.8K | $-0.01 |
| 2017 | $40.32M | $-768.1K | $-0.02 |
| 2016 | $39.39M | $4.25M | $0.15 |
| 2015 | $35.77M | $-1.85M | $-0.08 |
| 2014 | $35.53M | $-679.1K | $-0.03 |
| 2013 | $32.03M | $-6.68M | $-0.32 |
| 2012 | $33.61M | $-9.66M | $-0.56 |
Valuation
FOCLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-66.67%Social Signal Score
Mentions (4)
- Newsmarketbeat.com·53d ago·Neutral
FocalTherics Q2 Earnings Call Highlights FocalTherics NASDAQ: FOCL reported second-quarter HIFU revenue of $13.2 million, up 39% from $9.5 million a year earlier, as the company continued to expand sales of its Focal One high-intensity focused ultrasound platform for focal therapy.
View source ↗ - Newsglobenewswire.com·55d ago·Negative
FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares FocalTherics™ Announces Pricing of Public Offering of American Depositary Shares AUSTIN, Texas and LYON, France, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (NASDAQ: FOCL) (the “Company”), a global leader in robotic energy-based therapies, announced the pricing of its underwritten public offering of 8,425,000 of American Depositary Shares (“ADSs”), each representing one ordinary share of the Company, €0.13 nomin
View source ↗ - Newsglobenewswire.com·55d ago·Positive
FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026 FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026 AUSTIN, Texas, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced preliminary unaudited financial results for the Company's HIFU segment, reported as continuing operations, for the second quarter of 2026. During the second quarter of 2026, the Extracorpo
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
FocalTherics™ Announces Proposed Public Offering of American Depositary Shares FocalTherics™ Announces Proposed Public Offering of American Depositary Shares AUSTIN, Texas and LYON, France, Aug. 11, 2026 (GLOBE NEWSWIRE) -- FocalTherics™ (NASDAQ: FOCL) (the “Company”), a global leader in robotic energy-based therapies, announced today that it has commenced an underwritten public offering of American Depositary Shares (“ADSs”), each representing one ordinary share of the Company, €0.13 nominal va
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.23 per share
Typical surprise -17.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.39 vs $-0.20miss
- Thu, May 7$-0.24 vs $-0.20miss
- Wed, Mar 25$-0.25 vs $-0.15miss
- Thu, Nov 6$-0.15 vs $-0.25beat
- Thu, Aug 28$-0.18 vs $-0.21beat
- Thu, May 15$-0.21 vs $-0.16miss
Estimates and results for FOCL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by FOCL officers and directors.
- Bought
- $409k
- Sold
- —
4 trades
0 trades
- Schulz Franbought
- Willsey Lancebought
- Rhodes Ryanbought
- Shah Sanketbought
Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in FOCL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.